<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348489</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-110-04</org_study_id>
    <nct_id>NCT02348489</nct_id>
  </id_info>
  <brief_title>SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously&#xD;
      untreated AML who are not considered candidates for intensive remission induction&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2015</start_date>
  <completion_date type="Actual">June 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Complete Response (CR)</measure>
    <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
    <description>Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>At 676 death events (up to 38 months)</time_frame>
    <description>Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite CR (CRc)</measure>
    <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
    <description>CRc is reported as the number of participants with a best response of CR, complete response with incomplete platelet recovery (CRp), or complete response with incomplete blood count recovery (CRi).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Alive and Out of the Hospital</measure>
    <time_frame>Month 6</time_frame>
    <description>The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The Number of Days Alive and Out of the Hospital (NDAOH) was calculated as: NDAOH=180 - total duration of all hospital stays within 180 days from the first treatment - number of death days before Day 180. For subjects who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the subject would have died the day after the last contact day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
    <description>Progression-free survival was defined as the number of days from randomization to the earliest date of investigator's assessment of disease progression, participant receiving an alternative anti-leukemia therapy (including hematopoietic cell transplant), or relapse by peripheral blood (PB) assessment or blinded bone marrow (BM) assessment, whichever occurred first, or death, regardless of cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Red Blood Cell or Platelet Transfusions</measure>
    <time_frame>Month 6</time_frame>
    <description>The total number of red blood cells (RBCs) transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>EuroQol 5-level 5-dimension (EQ-5D-5L) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. Scores within each dimension for EQ-5D (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) were calculated using counts and proportions. Mean change in scores from baseline are summarized in which an index score of 0 represents the worst health state and 1 represents the best health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>EuroQol-Visual Analogue Scale (EQ-VAS) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. A vertical 20-cm scale for EQ-VAS was used where the lowest value of 0 was labeled &quot;the worst health you can imagine&quot; and the top value of 100 was labeled &quot;the best health you can imagine.&quot; Mean change in scores from baseline are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR</measure>
    <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
    <description>Duration of CR (in number of days) was calculated from the first time a CR was observed to the time of relapse, defined as the earliest time point whereby BM assessment or PB assessment indicated relapse/disease progression due to reappearance of leukemic blasts in PB or ≥ 5% leukemic blasts in BM.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">815</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>SGI-110 (guadecitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110 (guadecitabine)</intervention_name>
    <description>Investigational medicinal product</description>
    <arm_group_label>SGI-110 (guadecitabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Choice</intervention_name>
    <description>Choice of one: cytarabine, decitabine, or azacitidine</description>
    <arm_group_label>Treatment Choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cytologically or histologically confirmed diagnosis of AML (except M3 acute promyelocytic&#xD;
        leukemia) according to World Health Organization (WHO) classification.&#xD;
&#xD;
        Performance status (ECOG) of 0-3. Adults with previously untreated AML except for&#xD;
        hydroxyurea or corticosteroids. Prior hydroxyurea or lenalidomide treatment for&#xD;
        myelodysplastic syndrome (MDS) is allowed.&#xD;
&#xD;
        Not considered candidates for intensive remission induction chemotherapy at time of&#xD;
        enrollment based on EITHER:&#xD;
&#xD;
          1. ≥75 years of age OR&#xD;
&#xD;
          2. &lt;75 years of age with at least 1 of the following:&#xD;
&#xD;
        i. Poor performance status (ECOG) score of 2-3.&#xD;
&#xD;
        ii. Clinically significant heart or lung comorbidities, as reflected by at least 1 of:&#xD;
&#xD;
          1. Left ventricular ejection fraction (LVEF) ≤50%.&#xD;
&#xD;
          2. Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected.&#xD;
&#xD;
          3. Forced expiratory volume in 1 second (FEV1) ≤65% of expected.&#xD;
&#xD;
          4. Chronic stable angina or congestive heart failure controlled with medication.&#xD;
&#xD;
        iii. Liver transaminases &gt;3 × upper limit of normal (ULN).&#xD;
&#xD;
        iv. Other contraindication(s) to anthracycline therapy (must be documented).&#xD;
&#xD;
        v. Other comorbidity the investigator judges incompatible with intensive remission&#xD;
        induction chemotherapy, which must be documented and approved by the study medical monitor&#xD;
        before randomization.&#xD;
&#xD;
        Creatinine clearance as estimated by the Cockcroft-Gault (C-G) or other medically&#xD;
        acceptable formulas ≥30 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidate for intensive remission induction chemotherapy at the time of enrollment.&#xD;
&#xD;
        Candidate for best supportive care only, ie, not a candidate for any active therapy with&#xD;
        the TC comparators.&#xD;
&#xD;
        Known extramedullary central nervous system (CNS) AML.&#xD;
&#xD;
        Second malignancy currently requiring active therapy except breast or prostate cancer&#xD;
        stable on or responding to endocrine therapy.&#xD;
&#xD;
        Prior treatment with decitabine or azacitidine.&#xD;
&#xD;
        Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.&#xD;
&#xD;
        Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C&#xD;
        virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on&#xD;
        antivirals is allowed.&#xD;
&#xD;
        Known significant mental illness or other condition such as active alcohol or other&#xD;
        substance abuse or addiction that, in the opinion of the investigator, predisposes the&#xD;
        subject to high risk of noncompliance with the protocol.&#xD;
&#xD;
        Refractory congestive heart failure unresponsive to medical treatment; active infection&#xD;
        resistant to all antibiotics; or advanced pulmonary disease requiring &gt;2 liters per minute&#xD;
        (LPM) oxygen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Monarch Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus Wiener Gebietskrankenkasse</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <zip>6061</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Ghent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <state>West-vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Sveti Georgi' EAD</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Sveta Marina'' EAD</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>76B 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <state>Jihormoravsky KRAJ</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <state>Praha</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>Praha 10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet-Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Southern Finland</state>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse Cedex</city>
        <state>Alsace</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel-Dieu</name>
      <address>
        <city>Bayonne</city>
        <state>Aquitaine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri-Becquerel</name>
      <address>
        <city>Rouen Cedex 1</city>
        <state>Haute-normandie</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <state>Ile-de-france</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges Cedex</city>
        <state>Limousin, Lorraine</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Toulouse</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Midi-pyrenees</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel-Dieu</name>
      <address>
        <city>Nantes cedex 1</city>
        <state>PAYS DE LA Loire</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <state>Provence Alpes COTE D'azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <state>Provence Alpes COTE D'azur</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble</name>
      <address>
        <city>La Tronche</city>
        <state>Rhone-alpes</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <state>Rhone-alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <state>Rhone-alpes</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>Baden-wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt Goethe Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachsen</state>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Düsseldorf GmbH</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-holstein</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <state>Bacs-kiskun</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <state>Pesaro E Urbino</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Univesitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale di Busto Arsizio</name>
      <address>
        <city>Busto Arsizio</city>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto-Santo Bambino</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino - IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AORN A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria S. Maria della Misericordia di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno Gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Saint Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny im. M. Kopernika</name>
      <address>
        <city>Lódz</city>
        <state>Lodzkie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu - Samodzielny Publiczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Opole</city>
        <state>Opolskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich</name>
      <address>
        <city>Chorzów</city>
        <state>Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Tirgu-Mures</name>
      <address>
        <city>Targu-Mures</city>
        <state>Mures</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Regional de Oncologie Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Hospital</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes Universitetssjukhus i Lund</name>
      <address>
        <city>Lund</city>
        <state>Skane</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-LinKou Branch</name>
      <address>
        <city>Tao-Yuan</city>
        <state>Taoyuan</state>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <state>Kent</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <results_first_submitted>November 11, 2020</results_first_submitted>
  <results_first_submitted_qc>December 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2021</results_first_posted>
  <disposition_first_submitted>November 13, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 16, 2018</disposition_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>SGI-110</keyword>
  <keyword>DNA Hypomethylating Agen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guadecitabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02348489/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02348489/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 949 participants were assessed for inclusion in the study. Of these, 134 participants failed screening assessments and 815 participants were randomized.</recruitment_details>
      <pre_assignment_details>For the efficacy analysis (all randomized participants), the total duration was 38 months, with a median follow-up of 766 days (25.5 months), lower quartile follow-up of 671 days (22.4 months), and upper quartile follow-up of 896 days (29.9 months). For safety analysis (all treated participants), total duration was 51 months. Combining participants into a single group as part of the Treatment Choice arm was pre-specified as part of the study design.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SGI-110 (Guadecitabine)</title>
          <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Choice</title>
          <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="407"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="367"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="336"/>
                <participants group_id="P2" count="335"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>SGI-110 (Guadecitabine)</title>
          <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Choice</title>
          <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="408"/>
            <count group_id="B2" value="407"/>
            <count group_id="B3" value="815"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.9" spread="6.2"/>
                    <measurement group_id="B2" value="75.9" spread="5.8"/>
                    <measurement group_id="B3" value="75.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="242"/>
                    <measurement group_id="B3" value="473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="710"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="311"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="602"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Complete Response (CR)</title>
        <description>Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.</description>
        <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Complete Response (CR)</title>
          <description>Number of participants with a best response of CR assessed based on International Working Group 2003 acute myeloid leukemia (AML) response criteria by a blinded independent pathologist.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The complete response rate was compared between the treatment groups using a Cochran Mantel-Haenszel (CMH) test at an alpha level of 0.04 stratified to adjust for stratification factors used at randomization: age (&lt;75 or &gt;=75), Eastern Cooperative Oncology Group (ECOG) performance status (0-1, 2-3), study center region (North American, Europe, Rest of World), and secondary AML (secondary to MDS or other antecedent hematologic disorder) or poor-risk cytogenetics (Yes, No/Unknown).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.482</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rate (%)</param_type>
            <param_value>1.92</param_value>
            <ci_percent>96</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause.</description>
        <time_frame>At 676 death events (up to 38 months)</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival time was defined as the number of days from the day the participant was randomly assigned to study treatment to the date of death, regardless of cause.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="187" upper_limit="255"/>
                    <measurement group_id="O2" value="254" lower_limit="223" upper_limit="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Overall survival curves were estimated using Kaplan-Meier method and compared between the treatment groups using a 2-sided stratification log-rank test, stratified by the same factors used at randomization: age (&lt;75 or &gt;=75), Eastern Cooperative Oncology Group (ECOG) performance status (0-1, 2-3), study center region (North American, Europe, Rest of World), and secondary AML (secondary to MDS or other antecedent hematologic disorder) or poor-risk cytogenetics (Yes, No/Unknown).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7328</p_value>
            <method>Stratified log-rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite CR (CRc)</title>
        <description>CRc is reported as the number of participants with a best response of CR, complete response with incomplete platelet recovery (CRp), or complete response with incomplete blood count recovery (CRi).</description>
        <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens were administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite CR (CRc)</title>
          <description>CRc is reported as the number of participants with a best response of CR, complete response with incomplete platelet recovery (CRp), or complete response with incomplete blood count recovery (CRi).</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Alive and Out of the Hospital</title>
        <description>The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The Number of Days Alive and Out of the Hospital (NDAOH) was calculated as: NDAOH=180 - total duration of all hospital stays within 180 days from the first treatment - number of death days before Day 180. For subjects who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the subject would have died the day after the last contact day.</description>
        <time_frame>Month 6</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive and Out of the Hospital</title>
          <description>The date of each hospital admission and discharge was collected for each participant for up to 6 months, unless the participant died or withdrew consent prior to that time. Duration of each hospital stay in days was calculated as date of discharge minus date of admission. The Number of Days Alive and Out of the Hospital (NDAOH) was calculated as: NDAOH=180 - total duration of all hospital stays within 180 days from the first treatment - number of death days before Day 180. For subjects who were lost to follow-up within 6 months, the NDAOH was calculated conservatively assuming that the subject would have died the day after the last contact day.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" spread="63.6"/>
                    <measurement group_id="O2" value="105.7" spread="63.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Progression-free survival was defined as the number of days from randomization to the earliest date of investigator's assessment of disease progression, participant receiving an alternative anti-leukemia therapy (including hematopoietic cell transplant), or relapse by peripheral blood (PB) assessment or blinded bone marrow (BM) assessment, whichever occurred first, or death, regardless of cause.</description>
        <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens were administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Progression-free survival was defined as the number of days from randomization to the earliest date of investigator's assessment of disease progression, participant receiving an alternative anti-leukemia therapy (including hematopoietic cell transplant), or relapse by peripheral blood (PB) assessment or blinded bone marrow (BM) assessment, whichever occurred first, or death, regardless of cause.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="136" upper_limit="178"/>
                    <measurement group_id="O2" value="166" lower_limit="148" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Red Blood Cell or Platelet Transfusions</title>
        <description>The total number of red blood cells (RBCs) transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit.</description>
        <time_frame>Month 6</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Red Blood Cell or Platelet Transfusions</title>
          <description>The total number of red blood cells (RBCs) transfused or, separately, the total number of platelets transfused up to the 6-month time point for each participant was counted from the date of randomization to Day 180, the date of last contact, or date of death, whichever occurred earlier. One RBC or platelet transfusion was defined as one unit, and a single bag of RBCs or platelets was considered one unit.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>transfusion units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell Transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="11.84"/>
                    <measurement group_id="O2" value="15.6" spread="13.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Transfusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="18.78"/>
                    <measurement group_id="O2" value="14.4" spread="39.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L</title>
        <description>EuroQol 5-level 5-dimension (EQ-5D-5L) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. Scores within each dimension for EQ-5D (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) were calculated using counts and proportions. Mean change in scores from baseline are summarized in which an index score of 0 represents the worst health state and 1 represents the best health state.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-5D-5L</title>
          <description>EuroQol 5-level 5-dimension (EQ-5D-5L) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. Scores within each dimension for EQ-5D (mobility, self-care, usual activity, pain/discomfort, anxiety/depression) were calculated using counts and proportions. Mean change in scores from baseline are summarized in which an index score of 0 represents the worst health state and 1 represents the best health state.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="378"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7767" spread="0.2160"/>
                    <measurement group_id="O2" value="0.7663" spread="0.2291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8252" spread="0.1825"/>
                    <measurement group_id="O2" value="0.8240" spread="0.1948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0023" spread="0.1830"/>
                    <measurement group_id="O2" value="0.0112" spread="0.2325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS</title>
        <description>EuroQol-Visual Analogue Scale (EQ-VAS) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. A vertical 20-cm scale for EQ-VAS was used where the lowest value of 0 was labeled &quot;the worst health you can imagine&quot; and the top value of 100 was labeled &quot;the best health you can imagine.&quot; Mean change in scores from baseline are summarized.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life (QOL) Scores From Baseline: EQ-VAS</title>
          <description>EuroQol-Visual Analogue Scale (EQ-VAS) descriptive scores were collected for each participant for a minimum of 6 months, unless the participant died or withdrew consent. A vertical 20-cm scale for EQ-VAS was used where the lowest value of 0 was labeled &quot;the worst health you can imagine&quot; and the top value of 100 was labeled &quot;the best health you can imagine.&quot; Mean change in scores from baseline are summarized.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.64" spread="21.69"/>
                    <measurement group_id="O2" value="63.58" spread="21.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.76" spread="18.61"/>
                    <measurement group_id="O2" value="71.72" spread="18.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="177"/>
                    <count group_id="O2" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="19.35"/>
                    <measurement group_id="O2" value="3.67" spread="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of CR</title>
        <description>Duration of CR (in number of days) was calculated from the first time a CR was observed to the time of relapse, defined as the earliest time point whereby BM assessment or PB assessment indicated relapse/disease progression due to reappearance of leukemic blasts in PB or ≥ 5% leukemic blasts in BM.</description>
        <time_frame>Up to 38 months (median follow-up of 25.5 months)</time_frame>
        <population>The efficacy analysis set includes all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>SGI-110 (Guadecitabine)</title>
            <description>Guadecitabine 60 mg/m^2 was administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Choice</title>
            <description>One of the following treatment regimens was administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of CR</title>
          <description>Duration of CR (in number of days) was calculated from the first time a CR was observed to the time of relapse, defined as the earliest time point whereby BM assessment or PB assessment indicated relapse/disease progression due to reappearance of leukemic blasts in PB or ≥ 5% leukemic blasts in BM.</description>
          <population>The efficacy analysis set includes all randomized participants.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" lower_limit="175" upper_limit="261"/>
                    <measurement group_id="O2" value="231" lower_limit="182" upper_limit="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 51 months. Median (range) duration of treatment was 5 cycles (1-42) for SGI-110 and 5 cycles (1-37) for Treatment Choice (28 days per cycle). Treatment-emergent adverse events were events that first occurred or worsened after the first dose of study treatment until 30 days after the last dose or start of an alternative anti-leukemia treatment, whichever occurred first.</time_frame>
      <desc>Safety analysis set (randomized participants who received study treatment) was analyzed for TEAEs. All-cause mortality is presented for all randomized participants (participant flow shows number of deaths with primary reason for study withdrawal). Combining participants into a single group (Treatment Choice) was pre-specified as part of the study design and data for each treatment in that arm were not analyzed separately. Death is listed as an SAE when there is no identifiable cause or event.</desc>
      <group_list>
        <group group_id="E1">
          <title>SGI-110 (Guadecitabine)</title>
          <description>Guadecitabine 60 mg/m^2 was administered subcutaneously daily for 5 days (Days 1-5) in 28-day cycles.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Choice</title>
          <description>One of the following treatment regimens were administered: 20 mg cytarabine subcutaneously (SC) BID on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="407"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="401"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="147" subjects_affected="101" subjects_at_risk="401"/>
                <counts group_id="E2" events="138" subjects_affected="88" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemorrhagic diathesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Histiocytosis hematophagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lymphoadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lymphoadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Monoclonal B-cell lymphocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="401"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="13" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="401"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Mastoid disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colitis ischemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="401"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumatosis intestinalis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Small intestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Device related thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="401"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="401"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ischemic hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bacteroides bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Encephalomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Enterobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Escherichia bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroenteritis pseudomonas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hematoma infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatosplenic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Injection site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mucormycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pathogen resistance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Periumbilical abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="147" subjects_affected="117" subjects_at_risk="401"/>
                <counts group_id="E2" events="102" subjects_affected="79" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Post procedural cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="83" subjects_affected="62" subjects_at_risk="401"/>
                <counts group_id="E2" events="58" subjects_affected="44" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="401"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Septic vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="401"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemolytic transfusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Subdural hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscle hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Shoulder deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Biliary neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Central nervous system leukemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chloroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Endometrial cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tumor associated fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intracranial hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="401"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cystitis hemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Organizing pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute febrile neutrophilic dermatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rash generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="401"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lupus vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Shock hemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="401"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="401"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="401"/>
                <counts group_id="E2" subjects_affected="371" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="211" subjects_affected="88" subjects_at_risk="401"/>
                <counts group_id="E2" events="201" subjects_affected="78" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="103" subjects_affected="66" subjects_at_risk="401"/>
                <counts group_id="E2" events="57" subjects_affected="40" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="120" subjects_affected="37" subjects_at_risk="401"/>
                <counts group_id="E2" events="124" subjects_affected="33" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="319" subjects_affected="115" subjects_at_risk="401"/>
                <counts group_id="E2" events="233" subjects_affected="88" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="380" subjects_affected="116" subjects_at_risk="401"/>
                <counts group_id="E2" events="313" subjects_affected="101" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="43" subjects_affected="30" subjects_at_risk="401"/>
                <counts group_id="E2" events="50" subjects_affected="46" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="401"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="166" subjects_affected="125" subjects_at_risk="401"/>
                <counts group_id="E2" events="168" subjects_affected="114" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="169" subjects_affected="122" subjects_at_risk="401"/>
                <counts group_id="E2" events="116" subjects_affected="83" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="401"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="141" subjects_affected="91" subjects_at_risk="401"/>
                <counts group_id="E2" events="150" subjects_affected="108" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="46" subjects_at_risk="401"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="80" subjects_affected="58" subjects_at_risk="401"/>
                <counts group_id="E2" events="82" subjects_affected="66" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="61" subjects_at_risk="401"/>
                <counts group_id="E2" events="81" subjects_affected="55" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="97" subjects_affected="63" subjects_at_risk="401"/>
                <counts group_id="E2" events="74" subjects_affected="50" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="148" subjects_affected="73" subjects_at_risk="401"/>
                <counts group_id="E2" events="75" subjects_affected="48" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="125" subjects_affected="95" subjects_at_risk="401"/>
                <counts group_id="E2" events="108" subjects_affected="78" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="401"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="155" subjects_affected="89" subjects_at_risk="401"/>
                <counts group_id="E2" events="176" subjects_affected="110" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="401"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="401"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="401"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="401"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="401"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="64" subjects_affected="54" subjects_at_risk="401"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="22" subjects_at_risk="401"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="46" subjects_affected="33" subjects_at_risk="401"/>
                <counts group_id="E2" events="39" subjects_affected="28" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="401"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="401"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="47" subjects_affected="35" subjects_at_risk="401"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="116" subjects_affected="89" subjects_at_risk="401"/>
                <counts group_id="E2" events="80" subjects_affected="62" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="401"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="26" subjects_at_risk="401"/>
                <counts group_id="E2" events="43" subjects_affected="23" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="25" subjects_at_risk="401"/>
                <counts group_id="E2" events="29" subjects_affected="18" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="173" subjects_affected="96" subjects_at_risk="401"/>
                <counts group_id="E2" events="128" subjects_affected="77" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="50" subjects_affected="31" subjects_at_risk="401"/>
                <counts group_id="E2" events="36" subjects_affected="27" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="401"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="401"/>
                <counts group_id="E2" events="43" subjects_affected="36" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="401"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="51" subjects_affected="40" subjects_at_risk="401"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="47" subjects_affected="36" subjects_at_risk="401"/>
                <counts group_id="E2" events="56" subjects_affected="42" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="44" subjects_affected="32" subjects_at_risk="401"/>
                <counts group_id="E2" events="53" subjects_affected="38" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="401"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="401"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="38" subjects_at_risk="401"/>
                <counts group_id="E2" events="56" subjects_affected="45" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="401"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="100" subjects_affected="79" subjects_at_risk="401"/>
                <counts group_id="E2" events="83" subjects_affected="66" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="83" subjects_affected="63" subjects_at_risk="401"/>
                <counts group_id="E2" events="60" subjects_affected="51" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="71" subjects_affected="53" subjects_at_risk="401"/>
                <counts group_id="E2" events="51" subjects_affected="36" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="401"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="401"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="401"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="401"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="55" subjects_affected="41" subjects_at_risk="401"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="401"/>
                <counts group_id="E2" events="29" subjects_affected="19" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="401"/>
                <counts group_id="E2" events="37" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="401"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Harold Keer</name_or_title>
      <organization>Astex Pharmaceuticals, Inc.</organization>
      <phone>925-560-2913</phone>
      <email>harold.keer@astx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

